Global Epilepsy Therapeutics Market Set for Rapid Growth, To Reach Value Around USD 5,900 Million by 2024

Zion Market Research has published a new report titled “Epilepsy Therapeutics Market by Product Type (First-generation epilepsy therapeutics, Second-generation epilepsy therapeutics, and Third-generation epilepsy therapeutics) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 - 2024”. According to the report, global epilepsy therapeutics market was valued at approximately USD 4,500 million in 2017 and is expected to generate revenue of around USD 5,900 million by end of 2024, growing at a CAGR of around 3.9% between 2018 and 2024.

Epilepsy is repetitive episodes of sudden, extreme, and synchronous discharges in cerebral cortical neurons which results in disturbance of consciousness, interruption of sensation, movements, destruction of mental function, or combination of these signs. It is one of most common diseases diagnosed in old age people and children. Epilepsy or seizers are overactive and abnormal electrical action between the brain cells. The seizers may cause muscle spasm such as lip smacking and shake. The rising prevalence of neurological disorders is expected to propel the growth of epilepsy therapeutics market globally. According to WHO, about 2.4 million people each year are diagnosed with epilepsy globally. In high-income countries, 30-50 per 100,000 people are diagnosed with epilepsy annually. 

The epilepsy therapeutics market is segmented on the basis of product type, distribution channel, and by geography. Based on product type, the market is segmented into first-generation epilepsy therapeutics, second-generation epilepsy therapeutics, and third-generation epilepsy therapeutics. The first-generation epilepsy therapeutics includes ethosuximide, carbamazepine, phenytoin, phenobarbital, valproic acid, and primidone. Carbamazepine is the most widely prescribed drug for the treatment of partial and generalized seizures. The second generation epilepsy therapeutics includes Felbamate, Gabapentin, Lamotrigine, Levetiracetam, Oxcarbazepine, Pregabalin, Tiagabine, etc. The third-generation epilepsy therapeutics include Rufinamide, Eslicarbazepine acetate, Lacosamide, Perampanel, and Brivaracetam. The second generation epilepsy therapeutics accounted for high revenue share in the global epilepsy therapeutics market in 2017 owing to high safety and tolerability with a novel mechanism of action. The third generation epilepsy therapeutics is expected to register a high CAGR over the forecast period due to increasing adoption of technically advanced drugs.

Browse the full "Epilepsy Therapeutics Market by Product Type (First-generation epilepsy therapeutics, Second-generation epilepsy therapeutics, and Third-generation epilepsy therapeutics) and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 - 2024 " report at https://www.zionmarketresearch.com/report/epilepsy-therapeutics-market

On the basis of the distribution channel, the global epilepsy therapeutics market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The retail pharmacy accounted for the highest share in the global epilepsy therapeutics market owing to the easy availability of anti-epileptic drugs on retail pharmacy. The online pharmacy segment is estimated to register high growth rate in the coming years by distribution channel in the global epilepsy therapeutics market. The growing trend of digitalization is expected to boost the growth of the segment globally. 

Some of the key players in epilepsy therapeutics market include Eisai Co., Ltd., GlaxoSmithKline, Pfizer Inc., UCB S.A., Sumitomo Dainippon Pharma Co., Ltd., Janssen Pharmaceutical, Abbott, Novartis AG, and Shire. The growing mergers and partnership among the key players of epilepsy therapeutics market are expected to boost the growth of market in the near future. Moreover, growing research and development activity for development of newer and advanced treatment therapy is expected to boost the growth of the market globally. 

This report segments the global epilepsy therapeutics market as follows:

Global Epilepsy Therapeutics Market: Product Type Segment Analysis

• First-generation epilepsy therapeutics
• Second-generation epilepsy therapeutics
• Third-generation epilepsy therapeutics

Global Epilepsy Therapeutics Market: Distribution Channel Segment Analysis

• Hospital Pharmacy
• Retail pharmacy
• Online pharmacy 

Global Epilepsy Therapeutics Market: Regional Segment Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com